CSL Ltd (CSLLY PINK) stock market data APIs
$25.2485
-0.23(-0.9%)
as of March 4, 2026
Try our APIs with
free plan!
CSL Ltd Financial Data Overview
Price chart is built with
Anychart
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Prev. Close
25.2485
Open
25.0173
High
25.6223
Low
24.6995
52 wk Range
24.7-44.0069
Market Cap
49 695 M
P/E Ratio
8.276
Shares Outstanding
970 M
Revenue
15 407 M
EPS
0.82
Dividends (Yield)
0.0286
Beta
0.207
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CSL Ltd data using free add-ons & libraries
Get CSL Ltd Fundamental Data
CSL Ltd Fundamental data includes:
- Net Revenue: 15 407 M
- EBITDA: 4 840 M
- Earnings Per Share: 3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-10
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CSL Ltd News
New
CSLLY or EXAS: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with CSL Limited Sponsored ADR (CSLLY) and Exact Sciences (EXAS). But which of these two stocks presents investors ...
Eli Lilly's Landmark Trial Shows Major Psoriasis-Obesity Breakthrough With Taltz-Zepbound Combo
Eli Lilly and Co.(NYSE:LLY) on Wednesday shared topline results from the landmark TOGETHER-PsO open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide...
There May Be Some Bright Spots In CSL's (ASX:CSL) Earnings
The most recent earnings report from CSL Limited (ASX:CSL) was disappointing for shareholders. Despite the soft profit numbers, our analysis has optimistic about the overall quality of the income stat...
CSLLY vs. EXAS: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either CSL Limited Sponsored ADR (CSLLY) or Exact Sciences (EXAS). But which of these two stocks off...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
